Collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital), also known as COL2A1, is a humangene that provides instructions for the production of the pro-alpha1(II) chain of type II collagen.
Gene
The COL2A1 gene is located on the long (q) arm of chromosome 12 between positions 13.11 and 13.2, from base pair 46,653,017 to base pair 46,684,527. The expression of COL2A1 is regulated by SOX-9 and retrotransposon gag-like-3 gene RTL3 in chondrocytes.[5]
There are two transcripts identified for this gene.[6]
Function
This gene encodes the alpha-1 chain of type II collagen, a fibrillar collagen found in cartilage and the vitreous humor of the eye.[6]
Type II collagen, which adds structure and strength to connective tissues, is found primarily in cartilage, the jelly-like substance that fills the eyeball (the vitreous), the inner ear, and the center portion of the discs between the vertebrae in the spine (nucleus pulposus). Three pro-alpha1(II) chains twist together to form a triple-stranded, ropelike procollagen molecule. These procollagen molecules must be processed by enzymes in the cell. Once these molecules are processed, they leave the cell and arrange themselves into long, thin fibrils that cross-link to one another in the spaces around cells. The cross-linkages result in the formation of very strong mature type II collagen fibers.[6]
Several kinds of mutations in the COL2A1 gene are responsible for Achondrogenesis type 2. These include missing pieces of the gene, substitution of the amino acidglycine with another amino acid, or changes that result in truncated proteins. All these mutations disrupt the production of mature type II collagen, affecting tissues rich in this collagen.
Platyspondylic lethal skeletal dysplasia, Torrance type
Fewer than 10 COL2A1 mutations have been identified in people with Platyspondylic lethal skeletal dysplasia, Torrance type. Most result in a single amino acid change in the pro-alpha1(II) chain, producing an abnormal chain that cannot be incorporated into collagen fibers. This leads to reduced collagen production and skeletal abnormalities such as short limbs, small chest, flattened vertebrae, and short fingers and toes.
Hypochondrogenesis
Hypochondrogenesis is caused by various COL2A1 mutations, including deletions, glycine substitutions, and truncations. These interfere with the formation of mature, triple-stranded type II collagen molecules, affecting collagen-rich tissues.
Kniest dysplasia
Most mutations responsible for Kniest dysplasia result in abnormally short pro-alpha1(II) collagen chains that combine with normal-length chains, producing shorter-than-normal collagen molecules. This results in the characteristic features of Kniest dysplasia.
Spondyloepimetaphyseal dysplasia
All known COL2A1 mutations in Spondyloepimetaphyseal dysplasia, Strudwick type replace glycine with another amino acid in the pro-alpha1(II) chain, disrupting the formation of stable, triple-stranded collagen molecules.
Spondyloepiphyseal dysplasia congenita is caused by several types of COL2A1 mutations, including incorrect amino acid substitutions and truncated pro-alpha1(II) chains, impairing the formation of mature collagen molecules.[9]
In Spondyloperipheral dysplasia, COL2A1 mutations produce a truncated pro-alpha1(II) chain that cannot be incorporated into collagen fibers. The abnormal chains accumulate in cartilage cells, disrupting bone development and resulting in flattened vertebrae and short digits.
Stickler syndrome
Several COL2A1 mutations cause Stickler syndrome, often leading to the production of a truncated protein that cannot be incorporated into collagen fibers. Many mutations introduce premature stop signals, resulting in a 50% reduction of pro-alpha1(II) collagen chains and underproduction of type II collagen in cartilage.[10]
Osteoarthritis risk
Variations in the COL2A1 gene may increase susceptibility to osteoarthritis in some individuals. These variations alter amino acids in the pro-alpha1(II) chain, potentially affecting collagen fiber integrity in joint cartilage and contributing to degenerative joint disease.
^Zhang B, Zhang Y, Wu N, Li J, Liu H, Wang J (March 2020). "Integrated analysis of COL2A1 variant data and classification of type II collagenopathies". Clinical Genetics. 97 (3): 383–395. doi:10.1111/cge.13680. PMID31758797.
Donoso LA, Edwards AO, Frost AT, Ritter R, Ahmad N, Vrabec T, et al. (2003). "Clinical variability of Stickler syndrome: role of exon 2 of the collagen COL2A1 gene". Survey of Ophthalmology. 48 (2): 191–203. doi:10.1016/S0039-6257(02)00460-5. PMID12686304.
Fernandes RJ, Wilkin DJ, Weis MA, Wilcox WR, Cohn DH, Rimoin DL, et al. (July 1998). "Incorporation of structurally defective type II collagen into cartilage matrix in kniest chondrodysplasia". Archives of Biochemistry and Biophysics. 355 (2): 282–290. doi:10.1006/abbi.1998.0745. PMID9675039.
Meulenbelt I, Bijkerk C, De Wildt SC, Miedema HS, Breedveld FC, Pols HA, et al. (September 1999). "Haplotype analysis of three polymorphisms of the COL2A1 gene and associations with generalised radiological osteoarthritis". Annals of Human Genetics. 63 (Pt 5): 393–400. doi:10.1046/j.1469-1809.1999.6350393.x. PMID10735581. S2CID21918163.
Tiller GE, Polumbo PA, Weis MA, Bogaert R, Lachman RS, Cohn DH, et al. (September 1995). "Dominant mutations in the type II collagen gene, COL2A1, produce spondyloepimetaphyseal dysplasia, Strudwick type". Nature Genetics. 11 (1): 87–89. doi:10.1038/ng0995-87. PMID7550321. S2CID24826973.
Tysoe C, Saunders J, White L, Hills N, Nicol M, Evans G, et al. (September 2003). "A glycine to aspartic acid substitution of COL2A1 in a family with the Strudwick variant of spondyloepimetaphyseal dysplasia". QJM: Monthly Journal of the Association of Physicians. 96 (9): 663–671. doi:10.1093/qjmed/hcg112. PMID12925722.
Zabel B, Hilbert K, Stöss H, Superti-Furga A, Spranger J, Winterpacht A (May 1996). "A specific collagen type II gene (COL2A1) mutation presenting as spondyloperipheral dysplasia". American Journal of Medical Genetics. 63 (1): 123–128. doi:10.1002/(SICI)1096-8628(19960503)63:1<123::AID-AJMG22>3.0.CO;2-P. PMID8723097.
Zankl A, Neumann L, Ignatius J, Nikkels P, Schrander-Stumpel C, Mortier G, et al. (February 2005). "Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, torrance type, and define a novel subfamily within the type 2 collagenopathies". American Journal of Medical Genetics. Part A. 133A (1): 61–67. doi:10.1002/ajmg.a.30531. PMID15643621. S2CID24925027.
Zankl A, Zabel B, Hilbert K, Wildhardt G, Cuenot S, Xavier B, et al. (August 2004). "Spondyloperipheral dysplasia is caused by truncating mutations in the C-propeptide of COL2A1". American Journal of Medical Genetics. Part A. 129A (2): 144–148. doi:10.1002/ajmg.a.30222. PMID15316962. S2CID22472125.